<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524092</url>
  </required_header>
  <id_info>
    <org_study_id>16823</org_study_id>
    <secondary_id>I6T-MC-AMBG</secondary_id>
    <secondary_id>2017-003238-96</secondary_id>
    <nct_id>NCT03524092</nct_id>
  </id_info>
  <brief_title>A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <acronym>LUCENT 2</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of mirikizumab as
      maintenance therapy in participants who completed prior 12-week induction study AMAN
      (NCT03518086).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 4, 2018</start_date>
  <completion_date type="Anticipated">March 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Clinical Remission</measure>
    <time_frame>Week 40</time_frame>
    <description>Clinical remission based on modified Mayo Score (MMS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Endoscopic Remission</measure>
    <time_frame>Week 40</time_frame>
    <description>Endoscopic remission based on MMS Endoscopic Subscore (ES).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Mucosal Healing</measure>
    <time_frame>Week 40</time_frame>
    <description>Mucosal healing based on histology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Endoscopic Response</measure>
    <time_frame>Week 40</time_frame>
    <description>Endoscopic response based on the MMS ES.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Response</measure>
    <time_frame>Week 40</time_frame>
    <description>Clinical response based on the MMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 40 in Health Related Quality of Life</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>Health Related Quality of Life based on Inflammatory Bowel Disease Questionnaire (IBDQ) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 40 in Fecal Calprotectin</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>Change from baseline in fecal calprotectin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 40 in Ulcerative Colitis (UC) Symptoms: Numeric Rating Score (NRS)</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>UC symptoms based on NRS scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Hospitalized for UC</measure>
    <time_frame>Week 40</time_frame>
    <description>Percentage of participants hospitalized for UC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Clearance of Mirikizumab</measure>
    <time_frame>Weeks 0, 4, 12, 24, and 40</time_frame>
    <description>Clearance of mirikizumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1044</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mirikizumab Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab Dose #1 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab Dose #2 administered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab Dose #1</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Mirikizumab Dose #2</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and
             without early termination of study drug.

          -  Are willing and able to complete the scheduled study assessments, including endoscopy
             and daily diary entry.

          -  If female, must meet the contraception requirements.

        Exclusion Criteria:

          -  Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified
             (indeterminate colitis) during the induction study AMAN (NCT03518086).

          -  Participants with a bowel resection or other surgery for the treatment of UC during
             the previous induction study AMAN (NCT03518086), or are likely to require surgery for
             the treatment of UC during study AMBG.

          -  Participants with evidence of colonic dysplasia or have been diagnosed with cancer of
             the gastrointestinal tract during study AMAN (NCT03518086).

          -  Participants diagnosed with clinically important infection including, but not limited
             to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the
             induction study AMAN (NCT03518086).

          -  Participants who initiate a new prohibited medication during the induction study AMAN
             (NCT03518086).

          -  Participants with certain laboratory abnormalities prior to start of AMBG that would
             require permanent discontinuation from study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin-23 (IL-23)</keyword>
  <keyword>IL-23p19</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

